Since mutations in components of the Wnt pathway (such as in APC or β-catenin genes) contribute to aberrant activation of the β-catenin/T-cell factor-4 (TCF-4) complex that initiates most CRC (127) (Figure 1). This evidence concerns the gene TCF4 and colorectal carcinoma.